Abstract:BackgroundThe differential diagnosis of pancreatic ductal adenocarcinoma (PDAC) from chronic pancreatitis (CP) is clinically challenging due to a lack of minimally invasive diagnosis methods. MicroRNAs (miRNAs) derived from small extracellular vesicles (EVs) in the blood have been reported as a promising diagnosis biomarker for various types of cancer. However, blood small EV miRNA signatures and their diagnostic value to differentiate between PDAC and CP remain to be determined. MethodsIn this study, 107 patients with PDAC or CP were recruited, and 90 patients were finally enrolled for a training cohort (n = 48) and test cohort (n = 42). Small RNA sequencing was used to assess the expression of blood small EV miRNAs in these patients. ResultsThe linear model from the differentially expressed blood small EV miR-95-3p divided by miR-26b-5p showed an average sensitivity of 84.1% and an average specificity of 96.6% to identify PDAC from CP in the training cohort and the test cohort, respectively. When the model was combined with serum carbohydrate antigen 19-9 (CA19-9), the average sensitivity increased to 96.5%, and the average specificity remained at 96.4% of both cohorts, which demonstrated the best performance of all the published biomarkers for distinguishing between PDAC and CP. The causal analysis performed using the Bayesian network demonstrated that miR-95-3p was associated with a "consequence" of "cancer" and miR-26b-5p as a "cause" of "pancreatitis." A subgroup analysis revealed that blood small EV miR-335-5p/miR-340-5p could predict metastases in both cohorts and was associated with an overall survival (p = 0.020). ConclusionsThis study indicated that blood small EV miR-95-3p/miR-26b-5p and its combination with serum levels of CA19-9 could separate PDAC from CP, and miR-335-5p/miR-340-5p was identified to associate with PDAC metastasis and poor prognosis. These results suggested the potentiality of blood small EV miRNAs as differential diagnosis and metastases biomarkers of PDAC.

Differential Signature of Fecal Micrornas in Patients with Pancreatic Cancer

Combination of Plasma Micrornas with Serum Ca19-9 for Early Detection of Pancreatic Cancer

Circulating MiR-1290 As a Potential Diagnostic and Disease Monitoring Biomarker of Human Gastrointestinal Tumors

Elevated Expression of Exosomal Microrna-21 As a Potential Biomarker for the Early Diagnosis of Pancreatic Cancer Using a Tethered Cationic Lipoplex Nanoparticle Biochip.

Analysis of Serum Exosomal Micrornas and Clinicopathologic Features of Patients with Pancreatic Adenocarcinoma

Circulating MicroRNA Panel As a Diagnostic Marker for Hepatocellular Carcinoma

Altered profile of serum microRNAs in pancreatic cancer associated new-onset diabetes mellitus.

Plasma Mirnas Effectively Distinguish Patients With Pancreatic Cancer From Controls A Multicenter Study

Identification of Serum Circulating MicroRNAs as Novel Diagnostic Biomarkers of Gastric Cancer

Clinically Relevant Circulating Microrna Profiling Studies in Pancreatic Cancer Using Meta-Analysis

Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia

Diagnostic Plasma Small Extracellular Vesicles Mirna Signatures for Pancreatic Cancer Using Machine Learning Methods

Identification of a six‐miRNA panel in serum benefiting pancreatic cancer diagnosis

Circulating Micrornas As Specific Biomarkers for Breast Cancer Detection

MicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection

Plasma Microrna Panels To Diagnose Pancreatic Cancer: Results From A Multicenter Study

A Panel Of 13-Mirna Signature As A Potential Biomarker For Predicting Survival In Pancreatic Cancer

Serum Microrna Expression Profile As A Biomarker in the Diagnosis and Prognosis of Pancreatic Cancer

Fecal miR-29a and miR-224 as the noninvasive biomarkers for colorectal cancer.

Tumor-Specific miRNA Signatures in Combination with CA19-9 for Liquid Biopsy-Based Detection of PDAC

Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis